The University of Southampton
University of Southampton Institutional Repository

Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders

Reiter, Andreas, Grimwade, David and Cross, Nicholas C.P. (2007) Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders Haematologica, 92, (9), pp. 1153-1158. (doi:10.3324/haematol.10328).

Record type: Article


Eosinophilia is commonly observed in a wide range of disparate non-clonal and clonal disorders.1,2 In the majority of cases it is reactive, associated with atopic conditions, autoimmune disorders, infections or malignancies. In rare cases, a hematologic disorder underlies sustained eosinophilia which can be either non-clonal or clonal. The former (secondary eosinophilia) can be found in a variety of hematologic malignancies including Hodgkin’s disease and lymphomas, predominantly of T-cell phenotype. Hypereosinophilic syndrome (HES) is diagnosed when the blood eosinophil count is persistently greater than 1500/µL for at least 6 months with no evidence of a reactive condition or clonality. HES is a potentially life-threatening condition associated with end-organ damage to heart, gastrointestinal tract, skin, joints or nervous system due to release of granular contents from infiltrating eosinophils. In the lymphocytic variant (L-HES), clonal T-lymphocytes induce non-clonal eosinophil proliferation through overproduction of eosinophilopoietic cytokines such as IL-3, IL-5 or GM-CSF. Clonal or primary eosinophilia is generally associated with chronic myeloproliferative disorders (Eos-MPD), including atypical chronic myeloid leukemia (aCML), myeloproliferative variant of HES (M-HES), chronic myelomonocytic leukemia (CMML), unclassifiable overlap syndromes of myelodysplastic syndrome/myeloproliferative disorders (MDS/MPD) and systemic mastocytosis (SM). Chronic eosinophilic leukemia (CEL) is diagnosed in the presence of increased numbers of blasts and/or proof of clonality through cytogenetic or molecular analyses.

Full text not available from this repository.

More information

Published date: July 2007
Keywords: humans, research support, myeloproliferative disorders, diagnosis, editorial, eosinophilia, complications, therapy, research


Local EPrints ID: 60158
ISSN: 0390-6078
PURE UUID: f8092f6f-d0e5-4429-ac41-8bb88d2707ef
ORCID for Nicholas C.P. Cross: ORCID iD

Catalogue record

Date deposited: 05 Sep 2008
Last modified: 17 Jul 2017 14:23

Export record


Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.